Clinical trial
EPO906 in Carcinoid and Other Neuroendocrine Tumors
NCT00050349 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00050349 |
|---|---|
| Title | EPO906 in Carcinoid and Other Neuroendocrine Tumors |
| Official title | EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoid, Neuroendocrine Tumors |
| Intervention type | Drug |
| Interventions | EPO906 epothilone B |
| Enrollment | 33 |
| Start date | Jul 1, 2002 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Dec 5, 2002 |
| Last update posted | Mar 1, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: